Heritage Cannabis (CSE:CANN; OTCQX:HERTF) announced that Opticann, the medical brand and subsidiary of Heritage, is launching its first suite of CB4 branded products and has launched Opticann.ca in Canada.
Opticann medical cannabis products merge cannabis medicine with modern medicine. The products leverage pharmaceutical technology to maximize performance and safety. CB4 products are formulated based on the latest medical evidence and come in convenient dosage forms that deliver effective levels of cannabinoids.
The launch of CB4 products initially includes CB4 Control CBD & CBDA 10 mg filmstrips based on IntelGenx’s (TSXV:IGX; OTCQB:IGXT) Versafilm technology for rapid and maximum absorption from the sublingual cavity; Opticann’s CB4 Relief-T Softgels 25 mg formulated with VESIsorb technology; and CB4 Relief 0.5% Deep Rub Gel formulated with enhanced skin permeation technology for maximum effect. Additional Opticann CB4 products will be launched in coming weeks.
Last month, IntelGenx, which has recently transitioned to a commercial-stage from a development-stage company, shipped an initial order of the CBD film strips to Heritage in support of its CB4 Control CBD & CBDA 10 mg product launch.
“We believe all patients who may benefit from our products should have access, which is why we are offering CB4 products on multiple medical cannabis platforms in Canada,” Umar Syed, president of Heritage’s medical division, said in a statement.
“We are excited to introduce our revolutionary CB4 suite of medical products to Canada that are backed by objective scientific data that speaks to their superior performance and come in convenient dosage forms familiar to most medical patients – oral, topical and sublingual,” he added.
